ARVN News and Press, Arvinas Inc. From 02/17/22

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA 50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a mole...

– Bavdegalutamide demonstrated a 46% PSA 50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 evalua...

ARVN is doing superb, interesting science. If successful, this company could become a game-changer. They have some upcoming catalysts. For further details see: Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Guggen...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group –  As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s presenters provided very encourag...

Some of the biggest gainers this year were auto stocks. Ford saw its stock shoot up nearly 125% this year. Chairman Bill Ford Jr.’s insider purchase was through a trust and eclipses his previous $8 million purchase from Aug 2019. For further details see: Insider W...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is expected to enter two Phase 3 registrational clinical trials in 202...

Shares of ARVN (ARVN +2.2%) are higher this morning after Cowen initiated the company with an outperform rating. The firm does not have a price target. Analyst Tyler Van Buren cites potential for ARV-471 and ARV-110. The former is in phase 2 for ER+/HER- breast cancer and the latter in phase ...

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArget...